Bioventix delivered a strong set of interims, distorted by last year’s inclusion of c.£0.8m of back-dated royalty payments from one customer. Whilst statutory revenues rose 2% and pre-tax profits fell 5%, the underlying performance was considerably stronger, with revenues rising by 24% (21% CER) and underlying adjusted EPS up 27% to 53.8p. An interim dividend of 30p was declared (+20%), with net cash at period-end of £5.5m. Growth was driven by both Vitamin D antibody sales/
29 Mar 2019
Bioventix - The antibody that keeps on giving
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Bioventix - The antibody that keeps on giving
Bioventix Plc (BVXP:LON) | 4,475 0 0.0% | Mkt Cap: 233.6m
- Published:
29 Mar 2019 -
Author:
Mark Brewer -
Pages:
10
Bioventix delivered a strong set of interims, distorted by last year’s inclusion of c.£0.8m of back-dated royalty payments from one customer. Whilst statutory revenues rose 2% and pre-tax profits fell 5%, the underlying performance was considerably stronger, with revenues rising by 24% (21% CER) and underlying adjusted EPS up 27% to 53.8p. An interim dividend of 30p was declared (+20%), with net cash at period-end of £5.5m. Growth was driven by both Vitamin D antibody sales/